When was Kernal Biologics founded?

Kernal Biologics was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is Kernal Biologics located?

Kernal Biologics is headquartered in Cambridge, United States. It is registered at 700 Main Street, Cambridge, MA 02139.

How many employees does Kernal Biologics have?

As of Aug 31, 2026, the latest employee count at Kernal Biologics is 20.

Is Kernal Biologics a funded company?

Kernal Biologics is a funded company, having raised a total of $35.9M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 15, 2016.

When was the latest funding round of Kernal Biologics?

Kernal Biologics' latest funding was a $***** Grant (prize money) round on Oct 07, 2025, with participation from 1 investor.

Where does Kernal Biologics rank among its competitors?

Kernal Biologics ranks 200th amongst 3471 active competitors, of which 1160 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Kernal Biologics?

Kernal Biologics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Kernal Biologics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of mRNA therapeutics for immuno-oncology using deep learning technology. The company is developing platforms using deep learning algorithms and big data to design better mRNA therapeutics. The platform helps in three processes: codon-engineering, smart designing and non-immunogenic selection.

Website: kernalbio.com
Social
Email ID: *****@kernalbio.com
Phone Number: +1 **********
Registered Address: 700 Main Street, Cambridge, MA 02139

Key Metrics

Founded Year

2016

Location

Cambridge, United States

Stage

Series A

Total Funding

$35.9M in 6 rounds

Latest Funding Round

Grant (prize money), Oct 07, 2025, $*****

Investors

Hummingbird Ventures & 21 more

Ranked

200^th among 3471 active competitors

Employee Count

20 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3161 more

View Kernal Biologics' full profile

Kernal Biologics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
KERNAL BIOLOGICS, INC. CIN: 81-3590890 , United States, Active	Aug 17, 2016	-	18 (As on Dec 31, 2022)	-

Kernal Biologics has raised a total funding of $35.9M over 6 rounds. Its first funding round was on Sep 15, 2016. Its latest funding round was a Grant (prize money) round on Oct 07, 2025 for $*****. 1 investor participated in its latest round. Kernal Biologics has 22 institutional investors.

Here is the list of recent funding rounds of Kernal Biologics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 07, 2025	3723108	Grant (prize money)	2859670	8957631	3133077	1988208
Feb 25, 2022	3825858	Series A	4332495	2750053	9367086	Amgen & 2 more
Jul 22, 2021	2927881	Seed	1324071	7513055	Hummingbird Ventures	5221190

Access funding benchmarks and valuations. Sign up today!

View details of Kernal Biologics's funding rounds and investors

The founders of Kernal Biologics are Catherine Moroski Erkul, Yusuf Erkul and Burak Yilmaz.

Here are the details of Kernal Biologics' key team members:

Catherine Moroski Erkul: Co-Founder of Kernal Biologics.
Yusuf Erkul: Co-Founder & President of Kernal Biologics.
Contact Info: 1 email address
Burak Yilmaz: Co-Founder of Kernal Biologics.
Contact Info: 1 email address

View details of Kernal Biologics's Founder profiles and Board Members

Kernal Biologics' employee count trend

Kernal Biologics has 20 employees as of Aug 26. Here is Kernal Biologics's employee count trend over the years:

Employee count trend for Kernal Biologics

Uncover Kernal Biologics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kernal Biologics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Kernal Biologics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
200th	Kernal Biologics 2016, Cambridge (United States), Series A	Developer of mRNA therapeutics for immuno-oncology using deep learning technology	$35.9M	SymBiosis, Uncommon Denominator & 20 others	59/100